Advarra Unveils New Solution for Study Startup and Research Collaboration
End-to-end offering is designed to streamline site activation and optimize visibility in critical research processes.
Advarra has unveiled its Study Collaboration solution, a new offering designed to automate workflows in study startup and improve visibility among clinical trial stakeholders. The solution includes Advarra Study Startup (SSU) and Advarra Enroll as new products. Together, they guide teams through the site activation process and offer improved enrollment planning.1
In a press release, Ashley Davidson, vice president, product lead - sponsor tech strategy at Advarra said, "Study startup remains one of the most challenging aspects of clinical trials, and it takes time to progress through every milestone—from site identification and feasibility to ethics reviews, contract negotiations, and site training. Manual information exchange and disconnected systems often hinder coordination and visibility, creating delays that can cascade through the clinical trial timeline. Addressing these inefficiencies is critical to achieving enrollment goals, especially when 80% of trials fail to enroll patients on time."
The new Study Collaboration solution combines technology from Longboat, which was acquired by Advarra in 2020,2 with Advarra's study startup delivery program and industry-adopted single sign-on capabilities. The offering is provided by sponsors and CROs to research sites to collaborate on key processes such as feasibility assessments, document exchange, site training, milestone tracking, and enrollment planning.
Davidson added: "Our Study Collaboration solution represents a natural progression for Advarra, building on our role as a trusted partner to over 50,000 monthly research site users of our clinical trial management technology across more than 17,000 facilities. By automating workflows and integrating site activation processes such as regulatory submissions, document management, and training, we're reducing redundancies and saving valuable time. These enhancements strengthen collaboration between stakeholders, improve compliance, and accelerate research timelines, ultimately helping to bring new treatments to patients faster."
The Longboat technology behind Advarra’s Study Collaboration solution is an end-to-end platform for research sites and patients. It provides study teams with oversight of and engagement with sites globally and site staff with tools to focus on patient care while maintaining regulatory compliance. For patients and participants, the Longboat technology follows the entirety of their journey with capabilities such as dynamic protocol education tools, informed consent, visit reminders and guidance, and study updates.
In a press release from the time of the acquisition of Longboat, Gadi Saarony, CEO of Advarra said, “We’re thrilled to join forces with Longboat to progress our mutual vision of advancing clinical trials and accelerating drug development. By empowering sites and engaging patients through technology, Longboat creates a natural bridge from our IRB and IBC reviews and consulting services to our existing site-facing technology solutions, including OnCore, our clinical trial management system. Together, we provide comprehensive offerings to facilitate the clinical research journey, with sites and trial participants in mind. We look forward to welcoming Longboat to Advarra.”
References
1. Advarra Introduces Comprehensive Solution to Accelerate Study Startup and Improve Collaboration on Clinical Trials. News release. Advarra. January 21, 2025. Accessed January 22, 2025. https://www.prnewswire.com/news-releases/advarra-introduces-comprehensive-solution-to-accelerate-study-startup-and-improve-collaboration-on-clinical-trials-302355652.html
2. Advarra Acquires Longboat. News release. Advarra. November 23, 2020. Accessed January 22, 2025. https://www.advarra.com/about-advarra/news/advarra-acquires-longboat/
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Study Finds Many Randomized Clinical Trials Have Poorly Justified Exclusion Criteria
January 21st 2025Investigators find that most exclusion criteria in critical care randomized clinical trials are justifiable, but 60% include at least one poorly justified exclusion, most commonly affecting pregnant or lactating individuals.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
